Valuation Stories
Is Naas Technology ADR well positioned for April economic uncertainties?
few days ago at Macroaxis By Raphi Shpitalnik |
Naas Technology ADR (NASDAQ: NAAS), a player in the Specialty Retail sector, is showing promising signs of a robust rebound in April. Despite a net loss of $5.6 billion in the previous fiscal year and a high probability of bankruptcy at 96%, the company's current ratio stands at a healthy 3.48X, suggesting that it has more than enough resources to cover its short-term liabilities. Moreover, its total assets amount to $1.11 billion, while its total debt is considerably lower at $519.34 million, resulting in a low debt-to-equity ratio of 0.04%. Continue Reading...
- NAAS Naas Technology ADR
- Latest Nitel to Acquire WAN Dynamics
- NAAS 1.24 0.04
- Low 1.2
- High 1.28
- Volume 2.1 M
- Alpha -0.29
- Beta -0.37
- Return On Equity -3.07
- Return On Asset -0.35
- Operating Margin (1.37) %
- Current Valuation 383.48 M
- Shares Outstanding 257.58 M
- Shares Owned By Institutions 12.99 %
- Number Of Shares Shorted 1.87 M
- Price To Book 13.47 X
- Price To Sales 1.08 X
- Revenue 92.81 M
- Gross Profit 13.48 M
- EBITDA (2.45 B)
- Net Income (5.63 B)
- Cash And Equivalents 413.72 M
- Cash Per Share 1.93 X
- Total Debt 519.34 M
- Debt To Equity 0.04 %
- Current Ratio 3.48 X
- Book Value Per Share 0.74 X
- Cash Flow From Operations (580.7 M)
- Short Ratio 1.00 X
- Earnings Per Share (0.45) X
- Price To Earnings To Growth 3.06 X
- Target Price 4.65
- Number Of Employees 311
- Market Capitalization 309.09 M
- Total Asset 1.11 B
- Retained Earnings (6.03 B)
- Working Capital 738.65 M
- Z Score -13.71
- Net Asset 1.11 B
- Accumulation Distribution 130646.0
- Daily Balance Of Power 0.5
- Rate Of Daily Change 1.03
- Day Median Price 1.24
- Day Typical Price 1.24
- Price Action Indicator 0.02
- Period Momentum Indicator 0.04
- Relative Strength Index 67.88
Macroaxis uses a strict editorial review process to publish stories and blog posts. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
Reviewed by Gabriel Shpitalnik
Precigen has liabilities totaling 51.42 million with a Debt to Equity (D/E) ratio of 3.73, suggesting the company heavily depends on borrowing to finance its operations. The asset utilization ratio, which represents the revenue generated for each dollar of assets, is currently at 3.13 percent for Precigen. This means the company is generating $0.0313 for each dollar of assets.
over a week ago at Macroaxis By Vlad Skutelnik |
Buy when others are fearful, sell when others are greedy. This old adage might be applicable for investors considering Leggett Platt Incorporated, a prominent player in the Consumer Cyclical sector, specifically in the Furnishings, Fixtures & Appliances industry. Today, the stock took a dip, which could potentially present a buying opportunity.
over a month ago at Macroaxis By Nico Santiago |
The tide may be turning for Luther Burbank Corporation, a key player in the Banks - Regional industry. With a market capitalization of $479M and a current valuation of $1.46B, the company's financial health is under scrutiny as it navigates the choppy waters of the financial services sector. Despite a total revenue of $123.3M and a robust profit margin of 30.16%, Luther Burbank has been grappling with a quarterly revenue growth decline of 0.61%.
over a month ago at Macroaxis By Rifka Kats |
In the world of investments, the tide always turns. Whirlpool (WHR), a household durables heavyweight in the consumer cyclical industry, is poised for a potential upsurge in stock value come February 2024. Despite a challenging year with a net income loss of $1.6B and a net interest income loss of $426M, the company's fundamentals remain strong.
over a month ago at Macroaxis By Raphi Shpitalnik |
Money makes the world go round, and Truist Financial Corp (TFC) is no exception. As a key player in the Financial Services sector, specifically in the Banks - Regional industry, TFC has a current valuation of $87.74B. With a robust net income of $6.3B and a healthy profit margin of 25.94%, the company's financial health appears strong.
over two months ago at Macroaxis By Aina Ster |
Ambrx Biopharma (AMAM) is currently valued at a substantial $1.8B market capitalization, with a high price-to-book ratio of 7.30X, suggesting that the market may have overvalued the company. The firm's return on assets and equity are both negative, standing at a loss of 19% and 37% respectively, indicating potential inefficiencies in asset and equity management. Moreover, the company's EPS estimates for the current and next year are projected to be losses of $1.37 and $1.61 respectively, further hinting at potential financial struggles.
over two months ago at Macroaxis By Ellen Johnson |
Accolade Inc., a prominent player in the Health Care Technology sector, has seen a dip in its share prices today, presenting a potential buying opportunity for investors. Despite a net income loss of $459.6M, the company has shown promising signs of growth with a quarterly revenue growth of 10.5%. The company's current valuation stands at $870.81M with an enterprise value of $870.8M.
over two months ago at Macroaxis By Vlad Skutelnik |
The proof of the pudding is in the eating, and for Longboard Pharmaceuticals, the taste could be quite rewarding by February 2024. The clinical-stage biopharmaceutical company, with a focus on developing transformative medicines for neurological diseases, presents a potential investment opportunity, despite its current financial challenges. Longboard Pharmaceuticals, traded under the ticker LBPH on NASDAQ, has a net asset value of $70.62M and a current valuation of $536.38M.
over two months ago at Macroaxis By Gabriel Shpitalnik |
Redhill Biopharma currently has liabilities amounting to 122.69 million, with a Debt to Equity (D/E) ratio of 9.89. This suggests that the company may face challenges in generating sufficient cash to meet its financial obligations. Redhill Biopharma has a performance score of 11 on a scale of zero to one hundred.
over two months ago at Macroaxis By Vlad Skutelnik |